EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clonal hematopoiesis at the crossroads of Inflammaging and cardiovascular disease: Mechanistic insights and translational horizons

Soumiya Nadar iD, Taha K Dohadwala iD, Nitish Kumaresan, Shabbeer I Ahamed iD, Sumia Fatima iD

Clinical Hematology International · 23.12.2025 · 7 (4)

DOI: 10.46989/001c.146275 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Hematology International, online erschienen am 23.12.2025. Verfasst von Soumiya Nadar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Tbilisi State Medical University, 0186, Tbilisi, Georgia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clonal Hematopoiesis of indeterminate potential (CHIP) has been increasingly recognised as a risk factor for cardiovascular disease (CVD). Recent epidemiological and experimental studies have linked CHIP as an independent risk factor for myocardial infarction, stroke, and coronary artery disease, with specific mutations carrying a higher CVD risk. During the aging process, somatic mutations in genes, including DNMT3A and TET2, accumulate in the hematopoietic stem cells (HSCs), conferring both epigenetic and metabolic advantages that not only drive hematopoiesis towards a pro-inflammatory myeloid lineage but also reprogram innate immune cells, promoting a persistent inflammatory state. These myeloid derivatives, via increased IL-1β and IL-6 production, establish a pro-atherogenic environment and contribute to plaque instability, leading to an increased thrombotic risk and accelerated vascular aging. Although routine screening is not recommended for asymptomatic adults, targeted detection in high-risk individuals could benefit from preventive strategies. Incorporating CHIP into risk models may enable precision prevention, but prospective trials are needed to determine whether CHIP-guided interventions improve cardiovascular outcomes.

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular DiseasesClonal HematopoiesisInflammationMutationRisk Assessment

Autor:innen und Institutionen

  • Faculty of Medicine, Tbilisi State Medical University, 0186, Tbilisi, Georgia.
  • Department of Medicine, David Tvildiani Medical University, 0159, Tbilisi, Georgia.
  • Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Clinical Researcher, Clinical Trial Network, Houston, Texas, USA.

ORCID-Profile: Soumiya Nadar, Taha K Dohadwala, Shabbeer I Ahamed, Sumia Fatima

Zitieren

APA

Nadar, S., Dohadwala, T. K., Kumaresan, N., Ahamed, S. I., & Fatima, S. (2025). Clonal hematopoiesis at the crossroads of Inflammaging and cardiovascular disease: Mechanistic insights and translational horizons. Clinical Hematology International, 7(4). https://doi.org/10.46989/001c.146275

Vancouver

Nadar S, Dohadwala TK, Kumaresan N, Ahamed SI, Fatima S. Clonal hematopoiesis at the crossroads of Inflammaging and cardiovascular disease: Mechanistic insights and translational horizons. Clinical Hematology International. 2025;7(4). doi:10.46989/001c.146275

BibTeX
@article{Nadar2025,
  author = {Nadar, Soumiya and Dohadwala, Taha K and Kumaresan, Nitish and Ahamed, Shabbeer I and Fatima, Sumia},
  title = {Clonal hematopoiesis at the crossroads of Inflammaging and cardiovascular disease: Mechanistic insights and translational horizons},
  journal = {Clinical Hematology International},
  year = {2025},
  volume = {7},
  number = {4},
  doi = {10.46989/001c.146275}
}
Kostenlos starten →